• Dr Sarah O'Brien on the PREVAPIX-ALL trial

  • Dec 20 2023
  • Duración: 14 m
  • Podcast

Dr Sarah O'Brien on the PREVAPIX-ALL trial  Por  arte de portada

Dr Sarah O'Brien on the PREVAPIX-ALL trial

  • Resumen

  • Dr Sarah O'Brien joins Lan-Lan Smith to discuss results of the phase 3 PREVAPIX-ALL trial, which compares direct oral anticoagulant apixaban to low-molecular-weight-heparin for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma.

    Read the full article:
    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00314-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Más Menos
activate_primeday_promo_in_buybox_DT

Lo que los oyentes dicen sobre Dr Sarah O'Brien on the PREVAPIX-ALL trial

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.